Investors

Building the next phase of Disruptive Pharma

Disruptive Pharma is a Swedish pharmaceutical technology company developing and commercializing Formulite®, a patented and clinically evaluated platform technology for oral drug development.

Following the reverse takeover completed in July 2026, Disruptive Pharma is strengthening its commercial focus through new industry collaborations, strategic partnerships and continued investment in the development and scale-up of Formulite®.

“Our focus is increasingly shifting from demonstrating what Formulite® can do to translating the technology’s potential into business.”
Peter Åsberg, CEO